.tb-field[data-toolset-blocks-field="b3a43bd48fd19ec56cfe6ec7d64d7a1d"] { font-size: 13px;text-align: left;padding: 0px;margin: 0px; }  .tb-field[data-toolset-blocks-field="4195b6ea14ffd243700f97b8872ba332"] { font-size: 13px;text-align: left;padding: 0px;margin: 0px; }  .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .wpv-pagination-nav-links[data-toolset-views-view-pagination-block="c35d9a7279448f10d949ebc7e457ae45"] { text-align: left;justify-content: flex-start; } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] { background-color: rgba( 217, 217, 217, 0.13 );padding: 10px;margin-bottom: 15px;box-shadow: 5px 5px 10px 0 rgba( 0, 0, 0, 0.5 );border: 1px solid rgba( 215, 213, 213, 1 );grid-template-columns: minmax(0, 0.665fr) minmax(0, 0.335fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 } .tb-field[data-toolset-blocks-field="627e912eb953c8ed786ea0c7e10207ea"] { font-size: 14px;text-align: left;padding: 0px;margin: 0px; }  .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }   h1.tb-heading[data-toolset-blocks-heading="4273ccf7ca31e5697065fdb41a036bd2"]  { font-size: 26px; }  .wpv-custom-search-filter-submit[data-toolset-views-custom-search-submit="8ca7a9b3f80df5aa18fe74ad2a58d731"] { text-align: left; } @media only screen and (max-width: 781px) {   .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] { grid-template-columns: minmax(0, 0.5fr) minmax(0, 0.5fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 }  .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }     } @media only screen and (max-width: 599px) {   .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 }  .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }     } 

News and Press Releases

Pistoia Alliance Launches Initiative to Assess Sustainability of Digital vs. Traditional Clinical Trial Approaches

New initiative will collect pharma and CRO data to refine industry carbon measurement of technologies like remote monitoring and eConsent, informing more sustainable trial design 20 March 2025, Massachusetts, US...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 20, 2025

The Pistoia Alliance

info@pistoiaalliance.org

401 Edgewater Pl, Wakefield, Massachusetts, US

Innovaderm Research Rebrands as Indero, a dual-focus CRO

7 March 2025 -- Quebec, Canada -- Innovaderm, a leading clinical research organization (CRO), is excited to reveal a major rebranding to Indero, with immediate effect. The new brand identity...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 7, 2025

Indero

3530 Saint-Laurent boulevard, Suite 300 Montreal, QC, H2X 2V1, Canada

Schrödinger Selects Sapio Sciences to Enhance In Silico Drug Discovery From Plasmid to Structure

Configurable informatics platform improves lab efficiency, data tracking, and resource management from plasmid to structure 28 January 2025 – Baltimore, MD, US – Sapio Sciences, the science-aware™ lab informatics platform,...

Category: BioManufacturing, Drug Discovery
Posted: January 28, 2025

Sapio Sciences

400 East Pratt Street #800 Baltimore, MD 21202

PulseSight Therapeutics announces the initiation of the clinical plan of PST-611, Transferrin Vectorized Therapy for dry AMD/Geographic Atrophy

14 January 2025 -- Paris, France -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces it has submitted a Clinical...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 14, 2025

PulseSight Therapeutics

contact@pulsesight.com

PariSanté Campus, 2-10 Rue d’Oradour-sur-Glane, 75015 Paris

Biofidelity and CellCarta partner to deploy Aspyre Lung in global clinical trials

9 January 2025 -- Cambridge, UK and Montreal, Canada -- Biofidelity, a leader in innovative genomic solutions, and CellCarta, the global contract research organization (CRO) partner of choice for biopharmaceutical...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 9, 2025

Biofidelity

5151 McCrimmon Parkway, Suite 230 Morrisville, NC 27560

Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo Navacaprant showed an efficacy signal in...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 2, 2025

Neumora

investors@neumoratx.com

490 Arsenal Way, Suite 200 Watertown, MA 02472

Bioxodes meets enrollment milestone in Phase 2a intracerebral hemorrhagic stroke trial

Bioxodes has enrolled first 16 patients in trial with BIOX-101 Completing treatment of first cohort of patients will trigger interim analysis BIOX-101 is a first-in-class drug candidate, a peptide developed...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: December 19, 2024

Bioxodes

info@bioxodes.com

Parc d'activités Aéropole Rue Santos-Dumont, 1 6041 Gosselies, Belgique

Tracey Marantal Joins Worldwide Clinical Trials as President, Oncology Business Unit

Proven clinical operations leader joins global CRO to lead high-performing therapeutic team and drive strategy for growing oncology portfolio 24 September 2024 -- North Carolina, US -- Tracey Marantal has...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 24, 2024

Worldwide Clinical Trials

media@worldwide.com

600 Park Offices Drive Suite 200 Research Triangle Park, NC 27709 USA

Veridix AI, part of Emmes Group, Announces New Protocol Digitization Capabilities

Protocol digitization extracts structured data elements from unstructured text Automates database study builds, reducing build timelines by up to 30% Deployed within 40 study builds across Emmes CRO’s portfolio of...

Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: August 14, 2024

Veridix AI

401 N. Washington Street Suites 700 Rockville, MARYLAND 20850

Phase 2b Influenza Field Study Contract

hVIVO to enrol up to 1,000 healthy volunteers as part of a multicentre field study testing an influenza drug candidate, with hVIVO selected as the sole UK clinical site Largest...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: July 2, 2024

hVIVO

IR@hvivo.com

40 Bank Street, Floor 24, London, E14 5NR

Mage Biologics announces first subject dosed in a phase 1 trial with MB-001, an orally administered antibody for Inflammatory Bowel Disease

12 June 2024 -- Delaware, US -- Mage Biologics announces it has dosed the first study participant in a first-in-human study of MB-001, a best-in-class orally administered antibody designed for...

Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 19, 2024

Tillotts Pharma

tillotts@tillotts.com

Baslerstrasse 15 CH-4310 Rheinfelden Switzerland

Thermo Fisher Scientific Showcases Clinical Research Innovation at DIA Annual Meeting

PPD clinical research business leads real-world data and technology panel, receives CRO Leadership Award 17 June 2024 -- California, US -- The PPD clinical research business of Thermo Fisher Scientific,...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 17, 2024

Thermo Fisher Scientific

168 Third Avenue Waltham, MA 02451

Formycon reports on the results of the annual general meeting

Management provides detailed report on financial year 2023 and current company performance. Shareholders approve all agenda items and formally approve the acts of the members of the management board and...

Category: BioManufacturing
Posted: June 13, 2024

Formycon

inof@formycon.com

Formycon AG, Fraunhoferstraße 15, 82152 Martinsried/Planegg, Germany

Altasciences Receives 2024 CRO Leadership Award for Capabilities

16 May 2024 -- Laval, Québec, Canada -- Altasciences announced today that it has been recognised for excellence in contract research with a 2024 CRO Leadership Award for Capabilities. This...

Category: BioManufacturing, Clinical Trials, Pharmaceutical
Posted: June 3, 2024

Altasciences

contact@altasciences.com

575 Armand-Frappier Blvd. Laval, QC H7V 4B3 Canada

TMC welcomes Joe Lopez as Chief Financial Officer (CFO) to enhance corporate C-level team

3 June 2024 -- Hampshire, UK -- TMC Pharma Services, an established global product development and clinical research organisation (CRO) headquartered in Hampshire, UK, is pleased to announce the appointment...

Category: Clinical Trials, Pharmaceutical
Posted: June 3, 2024